Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
43
XERS Quote, Financials, Valuation and Earnings
Last price:
$6.11
Seasonality move
:
8.87%
Day range:
$5.80 - $6.62
52-week range:
$3.59 - $10.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.67x
P/B ratio:
--
Volume:
5.9M
Avg. volume:
1.7M
1-year change:
62.77%
Market cap:
$1B
Revenue:
$203.1M
EPS (TTM):
-$0.10
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XERS
Xeris Biopharma Holdings, Inc.
|
$86M | $0.05 | 39.22% | -70% | $11.14 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.6M | $0.14 | 15.84% | -39.29% | $31.80 |
|
CORT
Corcept Therapeutics, Inc.
|
$254.9M | $0.33 | 18.7% | -71.78% | $65.40 |
|
HROW
Harrow, Inc.
|
$88.4M | $0.48 | 43.33% | 150.93% | $70.63 |
|
IDXX
IDEXX Laboratories, Inc.
|
$1.1B | $2.94 | 11.88% | 15.54% | $750.23 |
|
VIR
Vir Biotechnology, Inc.
|
$19.9M | -$0.50 | -23.18% | -23.1% | $20.22 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XERS
Xeris Biopharma Holdings, Inc.
|
$6.12 | $11.14 | $1B | -- | $0.00 | 0% | 3.67x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$24.56 | $31.80 | $4.2B | 10.73x | $0.00 | 0% | 3.89x |
|
CORT
Corcept Therapeutics, Inc.
|
$35.70 | $65.40 | $3.8B | 43.64x | $0.00 | 0% | 5.62x |
|
HROW
Harrow, Inc.
|
$54.18 | $70.63 | $2B | -- | $0.00 | 0% | 8.09x |
|
IDXX
IDEXX Laboratories, Inc.
|
$656.73 | $750.23 | $52.4B | 50.21x | $0.00 | 0% | 12.36x |
|
VIR
Vir Biotechnology, Inc.
|
$9.09 | $20.22 | $1.3B | -- | $0.00 | 0% | 18.37x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XERS
Xeris Biopharma Holdings, Inc.
|
100.34% | -1.629 | 19.12% | 1.25x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 2.900 | 1.15% | 3.40x |
|
CORT
Corcept Therapeutics, Inc.
|
0.93% | -3.733 | 0.17% | 2.60x |
|
HROW
Harrow, Inc.
|
84.27% | 1.748 | 14.12% | 2.34x |
|
IDXX
IDEXX Laboratories, Inc.
|
37.81% | 1.136 | 1.81% | 0.71x |
|
VIR
Vir Biotechnology, Inc.
|
11.34% | 1.597 | 11.66% | 5.05x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XERS
Xeris Biopharma Holdings, Inc.
|
$60.7M | $6.7M | -6.45% | -1019.2% | 9.05% | $18.4M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
CORT
Corcept Therapeutics, Inc.
|
$199.6M | $4.5M | 14.82% | 14.97% | 2.22% | $38.4M |
|
HROW
Harrow, Inc.
|
$53.9M | $14.7M | -1.76% | -8.95% | 20.59% | $16.4M |
|
IDXX
IDEXX Laboratories, Inc.
|
$659.5M | $317M | 40.62% | 69.08% | 29.07% | $322.4M |
|
VIR
Vir Biotechnology, Inc.
|
$61.1M | -$48M | -42.14% | -46.56% | -74.92% | -$26.2M |
Xeris Biopharma Holdings, Inc. vs. Competitors
-
Which has Higher Returns XERS or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of 0.84% compared to Xeris Biopharma Holdings, Inc.'s net margin of 96.33%. Xeris Biopharma Holdings, Inc.'s return on equity of -1019.2% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital XERSXeris Biopharma Holdings, Inc.81.57% $0.00 $256.8M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About XERS or ACAD?
Xeris Biopharma Holdings, Inc. has a consensus price target of $11.14, signalling upside risk potential of 82.07%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.80 which suggests that it could grow by 29.48%. Given that Xeris Biopharma Holdings, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Xeris Biopharma Holdings, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XERSXeris Biopharma Holdings, Inc.5 1 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is XERS or ACAD More Risky?
Xeris Biopharma Holdings, Inc. has a beta of 0.642, which suggesting that the stock is 35.813% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock XERS or ACAD?
Xeris Biopharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XERS or ACAD?
Xeris Biopharma Holdings, Inc. quarterly revenues are $74.4M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Xeris Biopharma Holdings, Inc.'s net income of $621K is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Xeris Biopharma Holdings, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 10.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings, Inc. is 3.67x versus 3.89x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XERSXeris Biopharma Holdings, Inc.3.67x -- $74.4M $621K ACADACADIA Pharmaceuticals, Inc.3.89x 10.73x $284M $273.6M
-
Which has Higher Returns XERS or CORT?
Corcept Therapeutics, Inc. has a net margin of 0.84% compared to Xeris Biopharma Holdings, Inc.'s net margin of 11.83%. Xeris Biopharma Holdings, Inc.'s return on equity of -1019.2% beat Corcept Therapeutics, Inc.'s return on equity of 14.97%.
Company Gross Margin Earnings Per Share Invested Capital XERSXeris Biopharma Holdings, Inc.81.57% $0.00 $256.8M CORTCorcept Therapeutics, Inc.98.74% $0.20 $653.9M -
What do Analysts Say About XERS or CORT?
Xeris Biopharma Holdings, Inc. has a consensus price target of $11.14, signalling upside risk potential of 82.07%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $65.40 which suggests that it could grow by 83.19%. Given that Corcept Therapeutics, Inc. has higher upside potential than Xeris Biopharma Holdings, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Xeris Biopharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XERSXeris Biopharma Holdings, Inc.5 1 0 CORTCorcept Therapeutics, Inc.3 1 1 -
Is XERS or CORT More Risky?
Xeris Biopharma Holdings, Inc. has a beta of 0.642, which suggesting that the stock is 35.813% less volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.247, suggesting its less volatile than the S&P 500 by 75.347%.
-
Which is a Better Dividend Stock XERS or CORT?
Xeris Biopharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XERS or CORT?
Xeris Biopharma Holdings, Inc. quarterly revenues are $74.4M, which are smaller than Corcept Therapeutics, Inc. quarterly revenues of $202.1M. Xeris Biopharma Holdings, Inc.'s net income of $621K is lower than Corcept Therapeutics, Inc.'s net income of $23.9M. Notably, Xeris Biopharma Holdings, Inc.'s price-to-earnings ratio is -- while Corcept Therapeutics, Inc.'s PE ratio is 43.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings, Inc. is 3.67x versus 5.62x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XERSXeris Biopharma Holdings, Inc.3.67x -- $74.4M $621K CORTCorcept Therapeutics, Inc.5.62x 43.64x $202.1M $23.9M
-
Which has Higher Returns XERS or HROW?
Harrow, Inc. has a net margin of 0.84% compared to Xeris Biopharma Holdings, Inc.'s net margin of 1.42%. Xeris Biopharma Holdings, Inc.'s return on equity of -1019.2% beat Harrow, Inc.'s return on equity of -8.95%.
Company Gross Margin Earnings Per Share Invested Capital XERSXeris Biopharma Holdings, Inc.81.57% $0.00 $256.8M HROWHarrow, Inc.75.28% $0.03 $298.5M -
What do Analysts Say About XERS or HROW?
Xeris Biopharma Holdings, Inc. has a consensus price target of $11.14, signalling upside risk potential of 82.07%. On the other hand Harrow, Inc. has an analysts' consensus of $70.63 which suggests that it could grow by 30.35%. Given that Xeris Biopharma Holdings, Inc. has higher upside potential than Harrow, Inc., analysts believe Xeris Biopharma Holdings, Inc. is more attractive than Harrow, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XERSXeris Biopharma Holdings, Inc.5 1 0 HROWHarrow, Inc.7 0 0 -
Is XERS or HROW More Risky?
Xeris Biopharma Holdings, Inc. has a beta of 0.642, which suggesting that the stock is 35.813% less volatile than S&P 500. In comparison Harrow, Inc. has a beta of 0.073, suggesting its less volatile than the S&P 500 by 92.734%.
-
Which is a Better Dividend Stock XERS or HROW?
Xeris Biopharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harrow, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings, Inc. pays -- of its earnings as a dividend. Harrow, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XERS or HROW?
Xeris Biopharma Holdings, Inc. quarterly revenues are $74.4M, which are larger than Harrow, Inc. quarterly revenues of $71.6M. Xeris Biopharma Holdings, Inc.'s net income of $621K is lower than Harrow, Inc.'s net income of $1M. Notably, Xeris Biopharma Holdings, Inc.'s price-to-earnings ratio is -- while Harrow, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings, Inc. is 3.67x versus 8.09x for Harrow, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XERSXeris Biopharma Holdings, Inc.3.67x -- $74.4M $621K HROWHarrow, Inc.8.09x -- $71.6M $1M
-
Which has Higher Returns XERS or IDXX?
IDEXX Laboratories, Inc. has a net margin of 0.84% compared to Xeris Biopharma Holdings, Inc.'s net margin of 22.76%. Xeris Biopharma Holdings, Inc.'s return on equity of -1019.2% beat IDEXX Laboratories, Inc.'s return on equity of 69.08%.
Company Gross Margin Earnings Per Share Invested Capital XERSXeris Biopharma Holdings, Inc.81.57% $0.00 $256.8M IDXXIDEXX Laboratories, Inc.60.47% $3.08 $2.6B -
What do Analysts Say About XERS or IDXX?
Xeris Biopharma Holdings, Inc. has a consensus price target of $11.14, signalling upside risk potential of 82.07%. On the other hand IDEXX Laboratories, Inc. has an analysts' consensus of $750.23 which suggests that it could grow by 14.24%. Given that Xeris Biopharma Holdings, Inc. has higher upside potential than IDEXX Laboratories, Inc., analysts believe Xeris Biopharma Holdings, Inc. is more attractive than IDEXX Laboratories, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XERSXeris Biopharma Holdings, Inc.5 1 0 IDXXIDEXX Laboratories, Inc.5 5 1 -
Is XERS or IDXX More Risky?
Xeris Biopharma Holdings, Inc. has a beta of 0.642, which suggesting that the stock is 35.813% less volatile than S&P 500. In comparison IDEXX Laboratories, Inc. has a beta of 1.667, suggesting its more volatile than the S&P 500 by 66.736%.
-
Which is a Better Dividend Stock XERS or IDXX?
Xeris Biopharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IDEXX Laboratories, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings, Inc. pays -- of its earnings as a dividend. IDEXX Laboratories, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XERS or IDXX?
Xeris Biopharma Holdings, Inc. quarterly revenues are $74.4M, which are smaller than IDEXX Laboratories, Inc. quarterly revenues of $1.1B. Xeris Biopharma Holdings, Inc.'s net income of $621K is lower than IDEXX Laboratories, Inc.'s net income of $248.2M. Notably, Xeris Biopharma Holdings, Inc.'s price-to-earnings ratio is -- while IDEXX Laboratories, Inc.'s PE ratio is 50.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings, Inc. is 3.67x versus 12.36x for IDEXX Laboratories, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XERSXeris Biopharma Holdings, Inc.3.67x -- $74.4M $621K IDXXIDEXX Laboratories, Inc.12.36x 50.21x $1.1B $248.2M
-
Which has Higher Returns XERS or VIR?
Vir Biotechnology, Inc. has a net margin of 0.84% compared to Xeris Biopharma Holdings, Inc.'s net margin of -66.99%. Xeris Biopharma Holdings, Inc.'s return on equity of -1019.2% beat Vir Biotechnology, Inc.'s return on equity of -46.56%.
Company Gross Margin Earnings Per Share Invested Capital XERSXeris Biopharma Holdings, Inc.81.57% $0.00 $256.8M VIRVir Biotechnology, Inc.95.44% -$0.31 $863.1M -
What do Analysts Say About XERS or VIR?
Xeris Biopharma Holdings, Inc. has a consensus price target of $11.14, signalling upside risk potential of 82.07%. On the other hand Vir Biotechnology, Inc. has an analysts' consensus of $20.22 which suggests that it could grow by 122.47%. Given that Vir Biotechnology, Inc. has higher upside potential than Xeris Biopharma Holdings, Inc., analysts believe Vir Biotechnology, Inc. is more attractive than Xeris Biopharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XERSXeris Biopharma Holdings, Inc.5 1 0 VIRVir Biotechnology, Inc.7 0 0 -
Is XERS or VIR More Risky?
Xeris Biopharma Holdings, Inc. has a beta of 0.642, which suggesting that the stock is 35.813% less volatile than S&P 500. In comparison Vir Biotechnology, Inc. has a beta of 1.693, suggesting its more volatile than the S&P 500 by 69.258%.
-
Which is a Better Dividend Stock XERS or VIR?
Xeris Biopharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vir Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings, Inc. pays -- of its earnings as a dividend. Vir Biotechnology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XERS or VIR?
Xeris Biopharma Holdings, Inc. quarterly revenues are $74.4M, which are larger than Vir Biotechnology, Inc. quarterly revenues of $64.1M. Xeris Biopharma Holdings, Inc.'s net income of $621K is higher than Vir Biotechnology, Inc.'s net income of -$42.9M. Notably, Xeris Biopharma Holdings, Inc.'s price-to-earnings ratio is -- while Vir Biotechnology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings, Inc. is 3.67x versus 18.37x for Vir Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XERSXeris Biopharma Holdings, Inc.3.67x -- $74.4M $621K VIRVir Biotechnology, Inc.18.37x -- $64.1M -$42.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Feb 28
Applied Optoelectronics, Inc. [AAOI] is up 56.96% over the past day.
Buy
90
BNAI alert for Feb 28
Brand Engagement Network, Inc. [BNAI] is up 36.02% over the past day.
Sell
36
WLDN alert for Feb 28
Willdan Group, Inc. [WLDN] is down 25.56% over the past day.
